BCL6 Repression of EP300 in Human Diffuse Large B Cell Lymphoma Cells Provides a Basis for Rational Combinatorial Therapy Leandro C
Research article BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy Leandro C. Cerchietti,1,2 Katerina Hatzi,1,2 Eloisi Caldas-Lopes,3 Shao Ning Yang,1,2 Maria E. Figueroa,1,2 Ryan D. Morin,4 Martin Hirst,4 Lourdes Mendez,1 Rita Shaknovich,5 Philip A. Cole,6 Kapil Bhalla,7 Randy D. Gascoyne,8 Marco Marra,4 Gabriela Chiosis,3 and Ari Melnick1,2 1Hematology and Oncology Division, and 2Department of Pharmacology, Weill Cornell Medical College, New York, New York, USA. 3Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. 4Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 5Department of Pathology, Weill Cornell Medical College, New York, New York, USA. 6Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 7The University of Kansas Cancer Center, Kansas University Medical Center, Kansas City, Kansas, USA. 8Centre for Lymphoid Cancers and the Departments of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. B cell lymphoma 6 (BCL6), which encodes a transcriptional repressor, is a critical oncogene in diffuse large B cell lymphomas (DLBCLs). Although a retro-inverted BCL6 peptide inhibitor (RI-BPI) was recently shown to potently kill DLBCL cells, the underlying mechanisms remain unclear. Here, we show that RI-BPI induces a particular gene expression signature in human DLBCL cell lines that included genes associated with the actions of histone deacetylase (HDAC) and Hsp90 inhibitors.
[Show full text]